{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:13:21Z","timestamp":1783487601249,"version":"3.55.0"},"reference-count":40,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Brexu-cel is an established CD19-directed CAR-T cell therapy for relapsed or refractory mantle cell lymphoma, but clinical outcomes are heterogeneous, and germline determinants of response are poorly defined. Methods: We investigated the clinical impact of the CD19 single-nucleotide polymorphism rs2904880 on treatment outcome after brexu-cel CAR-T cell therapy by analyzing genotype-outcome associations in a retrospective single-center cohort of patients with relapsed or refractory mantle cell lymphoma treated with this CAR-T cell therapy. Results: Overall survival varied according to CD19 polymorphism, with improved survival of patients carrying the V174 homozygous genotype compared with L174V heterozygotes. Conclusions: The germline CD19 polymorphism may have implications for future risk stratification after brexu-cel CAR-T cell therapy in mantle cell lymphoma, but requires validation in larger, multicenter cohorts.<\/jats:p>","DOI":"10.3390\/cancers18132110","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:27:37Z","timestamp":1782746857000},"page":"2110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed\/Refractory Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"18","author":[{"given":"Simona Andrea","family":"Ruckstuhl","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Shaforostova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1736-812X","authenticated-orcid":false,"given":"Martina","family":"Bertschinger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland"},{"name":"Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle Cell Lymphoma in 2022\u2014A Comprehensive Update on Molecular Pathogenesis, Risk Stratification, Clinical Approach, and Current and Novel Treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","unstructured":"(2026, April 23). National Cancer Institute SEER Hematopoietic and Lymphoid Neoplasm Database, Available online: https:\/\/seer.cancer.gov\/seertools\/hemelymph\/51f6cf57e3e27c3994bd5357\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell Lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline Management of Mantle Cell Lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41375-026-02942-1","article-title":"Evolving Therapeutic Strategies in Mantle Cell Lymphoma: Advancements and Future Directions","volume":"40","author":"Tavarozzi","year":"2026","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101221","DOI":"10.1016\/j.blre.2024.101221","article-title":"Dismantling Relapsed\/Refractory Mantle Cell Lymphoma","volume":"67","author":"Ryan","year":"2024","journal-title":"Blood Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic Options for Relapsed\/Refractory Mantle Cell Lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023022353","article-title":"Treatment of Relapsed\/Refractory MCL","volume":"145","author":"Silkenstedt","year":"2025","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hon.2952","article-title":"Outcome of Patients with Mantle Cell Lymphoma after Autologous Stem Cell Transplantation in the pre-CAR T-cell Era","volume":"40","author":"Mathys","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell Therapy for the Management of Mantle Cell Lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wan, H., Weng, S., Sheng, S., Kuang, Z., Wang, Q., and Hu, L. (2024). Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1435127"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1182\/bloodadvances.2025017583","article-title":"Beyond the CAR-T Horizon in Mantle Cell Lymphoma","volume":"9","author":"Lew","year":"2025","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene Autoleucel for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in the United Kingdom: A Real-World Intention-to-Treat Analysis","volume":"8","author":"Wilson","year":"2024","journal-title":"HemaSphere"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma: A CIBMTR Analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2025-3606","article-title":"Real-World Effectiveness and Safety Outcomes by Age, Comorbidities, and Frailty among Relapsed or Refractory (R\/R) Mantle Cell Lymphoma (MCL) Patients Treated with Brexucabtagene Autoleucel (Brexu-Cel)","volume":"146","author":"Beitinjaneh","year":"2025","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2023-182415","article-title":"Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed\/Refractory Mantle Cell Lymphoma - First German\/Swiss Analysis","volume":"142","author":"Hess","year":"2023","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41409-022-01658-x","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Relapsed Mantle Cell Lymphoma: Real-World Experience from a Single Tertiary Care Center","volume":"57","author":"Heini","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2021-153277","article-title":"Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel","volume":"138","author":"Romancik","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Seipel, K., Abb\u00fchl, M., Bacher, U., Nilius, H., Daskalakis, M., and Pabst, T. (2023). Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. Cancers, 15.","DOI":"10.3390\/cancers15113058"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e012401","DOI":"10.1136\/jitc-2025-012401","article-title":"Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy","volume":"13","author":"Strati","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","unstructured":"(2026, May 22). U.S. Food and Drug Administration Approved Cellular and Gene Therapy Products, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejca.2021.10.022","article-title":"Disease-Specific Outcomes after Chimeric Antigen Receptor T-Cell Therapy","volume":"160","author":"Lemoine","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in Comparing the Impact of Costimulatory Domains on Approved CD19 CAR Functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO-24-02158","article-title":"Phase I\/II Study of Adaptive Manufactured Lentiviral Anti-CD20\/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma","volume":"43","author":"Shah","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14740\/wjon2534","article-title":"CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy","volume":"16","author":"Marshalek","year":"2025","journal-title":"World J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/therapeutics1020009","article-title":"Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma","volume":"1","author":"Seipel","year":"2024","journal-title":"Therapeutics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.2023022351","article-title":"Unraveling MCL Biology to Understand Resistance and Identify Vulnerabilities","volume":"145","author":"Sarkozy","year":"2025","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/blood-2024-205905","article-title":"Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma","volume":"144","author":"Yun","year":"2024","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e70123","DOI":"10.1002\/eji.70123","article-title":"Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy","volume":"56","author":"Peruzzi","year":"2026","journal-title":"Eur. J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"H\u00f6rtensteiner, L., Mandhair, H., Fischer, S., Seipel, K., Krebs, F.S., Zoete, V., Novak, U., Pabst, T., and Wehrli, M. (2026). The CD19 CAR T Hinge Region Influences Avidity and Cytotoxicity in CD19 SNP Variants in B-Cell Lymphoma (Preprint). Res. Sq.","DOI":"10.21203\/rs.3.rs-8865828\/v1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eadf1426","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR Antigen Engagement Mechanisms and Affinity Tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","article-title":"Point Mutation in CD19 Facilitates Immune Escape of B Cell Lymphoma from CAR-T Cell Therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1021\/acs.biochem.9b00808","article-title":"Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design","volume":"58","author":"Klesmith","year":"2019","journal-title":"Biochemistry"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:16:58Z","timestamp":1783484218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132110"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132110","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}